Laud the failure of J&J’s shot at patent evergreening
1 min read . 08:49 PM IST Last week, when the Indian Patent Office rejected an application by the US pharma major Johnson & Johnson to extend its patent on its TB drug Bedaquiline beyond its primary patent’s expiry this July, the decision was unanimously cheered by public health experts and policy observers in India and elsewhere
